ClinicalTrials.gg
CompletedNCT05013008FIGARO-BMUpdated Sep 15, 2023Results posted

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

A Phase 2 interventional study of Finerenone (Kerendia, BAY94-8862) and Placebo in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Completed at 115 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Bayer · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
951
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.

Enrollment
4th of 25
951 · median 100
Started
2021
the only one that year
Phase 2
4 of 25
none open now
Registered
3rd of 25
by date
Lead sponsor
8 of 25
Bayer

Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 2, and was the 3rd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing finerenone in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly. When CKD happens in people with type 2 diabetes mellitus, a condition characterized by high blood sugar levels, CKD is also referred to as diabetic kidney disease (DKD).

FIGARO-BM is an add-on study in which blood draws that were collected in the FIGARO-DKD study are further analyzed. No additional blood draws (also referred to as biological samples) or data will be obtained from the participants, nor will any additional or new study intervention be introduced. No visit or patient contact other than for obtaining the agreement by the patients (also called informed consent) will be required.

Inflammation and scarring are both seen as responsible for worsening of chronic kidney disease. There is much information from animal studies that the study treatment finerenone (BAY94-8862) works against inflammation and against scarring (also called fibrosis) in organs such as the kidney.

In this exploratory study researchers want to learn more about the study treatment finerenone (BAY94-8862). To find this out, this study will examine substances called biomarkers in blood draws from participants in the FIGARO-DKD study. Biomarkers are used as indicators of biological processes, disease processes or responses to medication. The biomarkers that will be examined stand for inflammation, organ scarring (also called fibrosis), blood vessel function and congestion.

The main question of this study is whether there are differences between these biomarkers in the group of participants who received finerenone and the group of participants who received a placebo in the FIGARO-DKD study. A placebo looks like a treatment but does not have any medicine in it. To answer this question, the researchers will compare the levels of these biomarkers between the two groups at different time points after starting the study treatment. Blood samples for this study will be obtained from FIGARO-DKD study sites with a high number of participants who had been treated with finerenone or placebo for at least 24 months. This information will be combined with other information from biomarker examinations already available in the FIGARO-DKD study.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will only include participants who were enrolled in the FIGARO-DKD study (NCT02545049) and had received up to 20 mg finerenone or placebo for ≥24 months.
  • For each participant, pharmacokinetic (PK) plasma samples from Visit 3 and at least 2 other Visits (Visit 5, Visit 8, Visit 11) must be available on storage from the main study FIGARO-DKD.

Exclusion criteria

Exclusion Criteria:

  • Participants which did not show overall compliance of 80 to 120% with study intervention in FIGARO-DKD.
  • Participants which were not part of the full analysis set (FAS) of FIGARO-DKD.
  • Participants with known fatal outcome.
  • Participants with baseline estimated (eGFR) ≤25 mL/min/1.73m\^2.
  • Participants with low baseline risk (normal albuminuria and eGFR≥60 mL/min/1.73m\^2).
  • Sponsor request (after discussion with the investigator), for reasons such as a significant protocol deviation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
951 participants (actual)

Study arms

  • Experimental
    Finerenone

    Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.

    Drug: Finerenone (Kerendia, BAY94-8862)

  • Placebo comparator
    Placebo

    Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.

    Drug: Placebo

Interventions

  • Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.

  • DrugPlacebo

    Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.

06

What researchers measure

Primary outcomes

  1. Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers

    The normalized protein expression (NPX) of biomarker levels were analyzed for the set of 27 pre-defined plasma biomarkers. NPX is a unit on log2-scale that is logarithmically related to protein concentration. Linear NPX (2\^NPX) was calcuated for descriptive analyses of the biomarker levels at each visit. Ratios of Visit 11 (36 months of treatment) to Visit 3 (4 months of treatment) were calculated to show the change in the plasma biomarker levels. Visit 3 (4 months of treatment) data were considered as baseline for the biomarker measurements as no pre-dose samples were available from FIGARO-DKD. Note, NPX units (Olink concentration units) are always relative units and can only be interpreted in the context of an individual study, i.e. to compare two conditions or timepoints ("change in NPX"). Equal nominal concentration values (same NPX units) for two different biomarkers measured by Olink Explore does not mean that both markers have the same absolute concentration.

    Time frame: At 4 months (Visit 3) of treatment and 36 months (Visit 11) of treatment

07

Results

Posted Mar 31, 2023
Limitations and caveats
This study was a retrospective, add-on study to the multi-center, interventional Phase 3 study FIGARO-DKD (NCT02545049). Blood plasma samples that were originally collected for PK analysis during the conduct of FIGARO-DKD study. Visit 3 (4 months of treatment) data were considered as baseline for the biomarker measurements as no pre-dose samples were available from FIGARO-DKD.

Participant flow

The study was conducted at multiple centers in 21 countries/regions between 18 August 2021 (first subject first visit) and 31 December 2021 (last subject last visit).

Participant flow — Overall Study
MilestoneFinerenonePlacebo
Started483468
Mbfas478443
Completed478443
Not completed525
Withdrew: Exclusion from mbfas525

Outcome measures

PrimaryMean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers

The normalized protein expression (NPX) of biomarker levels were analyzed for the set of 27 pre-defined plasma biomarkers. NPX is a unit on log2-scale that is logarithmically related to protein concentration. Linear NPX (2\^NPX) was calcuated for descriptive analyses of the biomarker levels at each visit. Ratios of Visit 11 (36 months of treatment) to Visit 3 (4 months of treatment) were calculated to show the change in the plasma biomarker levels. Visit 3 (4 months of treatment) data were considered as baseline for the biomarker measurements as no pre-dose samples were available from FIGARO-DKD. Note, NPX units (Olink concentration units) are always relative units and can only be interpreted in the context of an individual study, i.e. to compare two conditions or timepoints ("change in NPX"). Equal nominal concentration values (same NPX units) for two different biomarkers measured by Olink Explore does not mean that both markers have the same absolute concentration.

Time frame:
At 4 months (Visit 3) of treatment and 36 months (Visit 11) of treatment
Reported as:
Geometric mean · Ratio
Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers
RatioFinerenonePlacebo
Matrilysin (P09237)1.014 ± 1.1251.062 ± 1.201
von Willebrand factor (P04275)0.979 ± 1.7731.131 ± 1.765
CCN family member 4 (O95388)1.109 ± 1.2661.164 ± 1.329
Transforming growth factor beta-1 proprotein (P01137)1.122 ± 1.3121.184 ± 1.369
Transforming growth factor beta receptor type 3 (Q03167)1.133 ± 1.6871.224 ± 1.649
Interleukin-15 receptor subunit alpha (Q13261)1.121 ± 1.4021.179 ± 1.442
Metalloproteinase inhibitor 1 (P01033)1.056 ± 1.4561.105 ± 1.381
Pappalysin-1 (Q13219)1.088 ± 3.3711.273 ± 3.034
Proto-oncogene tyrosine-protein kinase Src (P12931)0.926 ± 2.9021.000 ± 2.492
Protein AMBP (P02760)1.034 ± 1.1681.045 ± 1.166
Uromodulin (P07911)0.980 ± 1.5130.956 ± 1.388
Aminopeptidase N (P15144)1.005 ± 1.2631.020 ± 1.316
Tumor necrosis factor receptor superfamily member 1A (P19438)1.151 ± 1.5061.184 ± 1.516
Plasminogen activator inhibitor 1 (P05121)0.945 ± 2.0890.972 ± 1.909
CCN family member 2 (P29279)1.083 ± 1.5481.103 ± 1.395
Urokinase plasminogen activator surface receptor (Q03405)1.109 ± 1.6611.127 ± 1.379
C-C motif chemokine 14 (Q16627)1.072 ± 1.6171.092 ± 1.401
C-C motif chemokine 16 (O15467)1.044 ± 1.6071.055 ± 1.416
Collagen alpha-1(I) chain (P02452)1.101 ± 1.6801.112 ± 1.534
Decorin (P07585)1.086 ± 1.2021.088 ± 1.250
C-C motif chemokine 2 (P13500)1.001 ± 1.3291.003 ± 1.409
Matrix metalloproteinase-9 (P14780)1.074 ± 2.3031.080 ± 2.108
E-selectin (P16581)1.009 ± 1.6811.010 ± 1.432
Thrombospondin-2 (P35442)1.054 ± 1.5331.056 ± 1.533
Retinoic acid receptor responder protein 2 (Q99969)1.035 ± 1.5691.022 ± 1.517
C-X-C motif chemokine 16 (Q9H2A7)1.058 ± 1.5621.063 ± 1.330
Dickkopf-related protein 3 (Q9UBP4)1.050 ± 1.4521.055 ± 1.427
Statistical analysis
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.001 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.002 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.044 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.044 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.127 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.210 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.215 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.215 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.745 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.762 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.762 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.762 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.762 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.917 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.917 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.917 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.917 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)
  • Finerenone vs Placebo · t-test, 2 sided · p = = 0.979 (Benjamini-Hochberg adjusted P-value was calculated using the log2-scaled NPX value.)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finerenone———
Placebo———

Baseline characteristics

Modified biomarker full analysis set (mBFAS): All participants with valid informed consent for this biomarker study, which met the following criteria: a. Study enrollment criteria as defined in the study protocol. b. Analyzed biomarker samples at Visit 3 (4 months) and Visit 11 (36 months); Biomarker samples that were shipped at ambient temperatures were not analyzed. c. On Treatment at Visit 3 and Visit 11.

Age, Continuous
Age, Continuous(years)FinerenonePlaceboTotal
Mean63.55 ± 9.5064.15 ± 9.6563.84 ± 9.57
Sex: Female, Male
Sex: Female, Male(Participants)FinerenonePlaceboTotal
Female120112232
Male358331689
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FinerenonePlaceboTotal
American Indian or Alaska Native101
Asian173151324
Native Hawaiian or Other Pacific Islander011
Black or African American8715
White293283576
More than one race202
Unknown or Not Reported112
Plasma biomarker levels after 4 months of treatment
Plasma biomarker levels after 4 months of treatment(Linear NPX (2^NPX))FinerenonePlaceboTotal
Matrilysin (P09237)19.618 ± 1.14818.956 ± 1.203NA ± NA
von Willebrand factor (P04275)3.200 ± 1.7932.338 ± 1.629NA ± NA
CCN family member 4 (O95388)1.600 ± 1.3371.578 ± 1.374NA ± NA
Transforming growth factor beta-1 proprotein (P01137)1.480 ± 1.3271.425 ± 1.349NA ± NA
Transforming growth factor beta receptor type 3 (Q03167)1.583 ± 1.6311.776 ± 1.624NA ± NA
Interleukin-15 receptor subunit alpha (Q13261)1.678 ± 1.4321.614 ± 1.450NA ± NA
Metalloproteinase inhibitor 1 (P01033)1.818 ± 1.4501.824 ± 1.349NA ± NA
Pappalysin-1 (Q13219)0.171 ± 3.0660.164 ± 2.762NA ± NA
Proto-oncogene tyrosine-protein kinase Src (P12931)1.770 ± 2.6141.535 ± 2.229NA ± NA
Protein AMBP (P02760)1.595 ± 1.2261.611 ± 1.225NA ± NA
Uromodulin (P07911)0.582 ± 1.7520.699 ± 1.531NA ± NA
Aminopeptidase N (P15144)1.224 ± 1.2731.248 ± 1.300NA ± NA
Tumor necrosis factor receptor superfamily member 1A (P19438)2.105 ± 1.6062.107 ± 1.575NA ± NA
Plasminogen activator inhibitor 1 (P05121)1.349 ± 2.1481.261 ± 1.868NA ± NA
CCN family member 2 (P29279)1.245 ± 1.5851.258 ± 1.360NA ± NA
Urokinase plasminogen activator surface receptor (Q03405)1.744 ± 1.6991.725 ± 1.398NA ± NA
C-C motif chemokine 14 (Q16627)3.013 ± 1.6673.056 ± 1.426NA ± NA
C-C motif chemokine 16 (O15467)1.625 ± 1.7761.633 ± 1.637NA ± NA
Collagen alpha-1(I) chain (P02452)0.646 ± 1.6750.693 ± 1.497NA ± NA
Decorin (P07585)1.523 ± 1.2331.526 ± 1.233NA ± NA
C-C motif chemokine 2 (P13500)3.065 ± 1.2853.209 ± 1.367NA ± NA
Matrix metalloproteinase-9 (P14780)1.329 ± 2.2021.176 ± 1.985NA ± NA
E-selectin (P16581)1.235 ± 1.8281.200 ± 1.577NA ± NA
Thrombospondin-2 (P35442)1.421 ± 1.6551.452 ± 1.649NA ± NA
Retinoic acid receptor responder protein 2 (Q99969)2.201 ± 1.5802.252 ± 1.418NA ± NA
C-X-C motif chemokine 16 (Q9H2A7)1.341 ± 1.5861.353 ± 1.338NA ± NA
Dickkopf-related protein 3 (Q9UBP4)1.827 ± 1.5411.925 ± 1.460NA ± NA
08

Study locations

115 sites
  • Valley Clinical Trials, Inc. - Northridge
    Northridge, California 91325, United States
  • Saviers Medical Group
    Port Hueneme, California 93041, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Florida Kidney Physicians - Fort Lauderdale
    Fort Lauderdale, Florida 33308, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Crescent City Clinical Research Center, LLC
    Metairie, Louisiana 70006, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Kansas City VA Medical Center
    Kansas City, Missouri 64128, United States
  • Randolph Medical Associates
    Asheboro, North Carolina 27203, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212-4740, United States
  • Illawarra Diabetes Service
    Wollongong, New South Wales 2500, Australia
  • Melbourne Renal Research Group
    Reservoir, Victoria 3073, Australia
  • Medizinische Universität Graz
    Graz, Steiermark 8036, Austria
  • Klinik Landstraße - Krankenhaus Rudolfstiftung
    Wien, 1030, Austria
  • Zentrum f. klinische Studien Dr. Hanusch GmbH
    Wien, 1060, Austria
  • UZ Gent
    Gent, 9000, Belgium
  • AZ Delta
    Roeselaere, 8800, Belgium
  • Multiprofile Hospital for Active Treatment St. Ivan Rilski - Gorna Oryahovitsa | Nephrology Department
    Gorna Oryahovitsa, 5100, Bulgaria
  • DCC 2 - Plovdiv EOOD
    Plovdiv, 4002, Bulgaria
  • MHAT Sveti Pantaleymon - Yambol
    Yambol, 8600, Bulgaria
  • Fraser Clinical Trials, Inc.
    New Westminster, British Columbia V3L 3W4, Canada
  • Hopital Charles LeMoyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • Manna Research (Mirabel)
    Mirabel, Quebec J7J 2K8, Canada
  • Clinique des Maladies Lipidques de Quebec
    Quebec, G1V 4W1, Canada
  • Nefrologicka ambulance
    Praha 4, 140 00, Czechia
  • Aarhus Universitetshospital, Skejby
    Aarhus N, 8200, Denmark
  • Sydvestjysk Sygehus Esbjerg, Endocrinology dept.
    Esbjerg, 6700, Denmark
  • Capital Region | Gentofte Hospital - Cardiology Research
    Hellerup, 2900, Denmark
  • Herlev Hospital - Endocrinology dept.
    Herlev, 2730, Denmark
  • Steno Diabetes Center Copenhagen
    Herlev, 2730, Denmark
  • Holbæk Sygehus
    Holbæk, 4300, Denmark
  • Holstebro Hospital, Endocrinology dept.
    Holstebro, DK-7500, Denmark
  • Bispebjerg Hospital
    København NV, 2400, Denmark
  • Viborg Sygehus
    Viborg, 8800, Denmark
  • Terveystalo Oulu
    Oulu, 90100, Finland
  • Lääkärikeskus Minerva
    Rauma, 26100, Finland
  • Turun yliopistollinen keskussairaala
    Turku, 20520, Finland
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital Hong Kong
    Shatin, Hong Kong
  • Tung Wah Hospital
    Sheung Wan, Hong Kong
  • Barzilai Medical Center | Nephrology & Hypertension Dept.
    Ashkelon, 7830604, Israel
  • Edith Wolfson Medical Center
    Holon, 5822012, Israel
  • Hadassah Hebrew University Hospital Ein Kerem
    Jerusalem, 9112001, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • The Nazareth Trust Hospital EMMS
    Nazareth, 16100, Israel
  • Clalit Health Services, Midgal Hamea
    Tel Aviv, 6203854, Israel
  • DMC - Diabetes Medical Center
    Tel Aviv, 6937947, Israel
  • A.O.U. di Bologna Policlinico S.Orsola Malpighi
    Bologna, Emilia-Romagna 40138, Italy
  • Istituto Ricerche Farmacologiche Mario Negri IRCCS
    Bergamo, Lombardia 24020, Italy
  • ASST Papa Giovanni XXIII
    Bergamo, Lombardia 24127, Italy
  • ASST Santi Paolo e Carlo
    Milano, Lombardia 20142, Italy
  • Kohnodai Hospital, NC for Global Health and Medicine
    Ichikawa, Chiba 272-8516, Japan
  • Saiseikai Matsuyama Hospital
    Matsuyama, Ehime 791-8026, Japan
  • Fukuoka University Chikushi Hospital
    Chikushino, Fukuoka 818-8502, Japan
  • Fukuoka Tokushukai Hospital
    Kasuga, Fukuoka 816-0864, Japan
  • Kokura Memorial Hospital
    Kitakyushu, Fukuoka 802-8555, Japan
  • Steel Memorial Yawata Hospital
    Kitakyushu, Fukuoka 805-8508, Japan
  • Shirakawa Kosei General Hospital
    Shirakawa, Fukushima 961-0005, Japan
  • Higashihiroshima Medical Center
    Higashihiroshima, Hiroshima 739-0041, Japan
  • Jiyugaoka YAMADA Clinic
    Obihiro, Hokkaido 080-0848, Japan
  • Nakakinen Clinic
    Naka, Ibaraki 311-0113, Japan
  • Noritake Clinic
    Ushiku, Ibaraki 300-1207, Japan
  • Komatsu Municipal Hospital
    Komatsu, Ishikawa 923-8560, Japan
  • Shonan Fujisawa Tokushukai Hospital
    Fujisawa, Kanagawa 251-0041, Japan
  • Shonan Kamakura General Hospital
    Kamakura, Kanagawa 247-8533, Japan
  • Osaka Saiseikai Senri Hospital
    Suita, Osaka 565-0862, Japan
  • Sugiura Clinic
    Kawaguchi, Saitama 332-0012, Japan
  • Association of healthcare corporation, Oyama East Clinic
    Oyama, Tochigi 323-0022, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto, 861-8520, Japan
  • Japanese Red Cross Nagasaki Genbaku Hospital
    Nagasaki, 852-8511, Japan
  • Kyosokai AMC NISHI-UMEDA Clinic
    Osaka, 530-0001, Japan
  • Kitano Hospital
    Osaka, 530-8480, Japan
  • Yonsei University Wonju Christian Hospital
    Wonju, Gang''weondo 26426, Korea, Republic of
  • Hallym University Sacred Heart Hospital
    Anyang-si, Gyeonggido 14068, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 03080, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Kyung Hee University Hospital at Gangdong
    Seoul, 05278, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 110-746, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 3722, Korea, Republic of
  • Albert Schweitzer Ziekenhuis, locatie Zwijndrecht
    Zwijndrecht, 3331 LZ, Netherlands
  • Centro Clinico Academico - Braga
    Braga, 4710-243, Portugal
  • First City Clinical Hospital n.a. E.E. Volosevich
    Arkhangelsk, 163001, Russian Federation
  • Izhevsk City Clinical Hospital #9
    Izhevsk, 426063, Russian Federation
  • Sci-Res. Institute of Complex Cardiovascular Disorders
    Kemerovo, 650002, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • Center of cardiology and neurology
    Kirov, 610014, Russian Federation
  • Regional Clinical Hospital #1 n.a. prof. S.V. Ochapovsky
    Krasnodar, 350086, Russian Federation
  • Moscow State University n.a. M.V. Lomonosov
    Moscow, 119192, Russian Federation
  • Moscow State Univ. of Med. & Stomatology n.a. A.I. Evdokimov
    Moscow, 123182, Russian Federation
  • PHI "Central Clinical Hospital "RZD-Medicine"
    Moscow, 125315, Russian Federation
  • City Clinical Hospital #13 Nizhny Novgorod
    Nizhny Novgorod, 603018, Russian Federation
  • Saratov City Clinical Hospital #9
    Saratov, 410030, Russian Federation
  • Voronezh Regional Clinical Consultancy-Diagnostic Center
    Voronezh, 394018, Russian Federation
  • City Outpatient Clinic #4
    Voronezh, 394077, Russian Federation
  • Clinical Hospital for Emergency Care n.a. N.V.Solovyov
    Yaroslavl, 150003, Russian Federation
  • Singapore General Hospital
    Singapore, 169608, Singapore

Showing the first 100 of 115 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2021, 4 months.

Results were first posted in Mar 2023, 1 year 3 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 4 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Aug 19, 2021
StartActual
Aug 18, 2021
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2021
Results first posted
Mar 31, 2023
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05013008
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 19, 2021
Start date
Aug 18, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Results posted
Mar 31, 2023
Last update
Sep 15, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion